Aktis Oncology, Inc.
NASDAQ Global SelectTotal Valuation
Aktis Oncology, Inc. carries a market capitalization of 1.06B, placing it among publicly traded companies globally. Its enterprise value stands at 174,324.28, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.06B |
| Enterprise Value | 174,324.28 |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | 0.02 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | -0.01 |
| P/OCF Ratio | 0.00 |
Enterprise Valuation
| EV / Sales | 0.02 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Aktis Oncology, Inc. maintains a current ratio of 34.97, meaning it holds 35.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 34.97 |
| Quick Ratio | 34.95 |
| Debt / Equity | -122.43 |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -264.81 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 4.39 |
Taxes
| Income Tax | 2,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Aktis Oncology, Inc.'s stock has declined approximately -11.11607% over the past 52 weeks. The 50-day moving average sits at 18.94, while the 200-day moving average is 19.30.
| Beta (5Y) | N/A |
| 52-Week Price Change | -11.11607% |
| 50-Day Moving Average | 18.94 |
| 200-Day Moving Average | 19.30 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Aktis Oncology, Inc. generated 8.24M in revenue and converted that into -135.84M in net income, yielding earnings per share of -3.90. EBITDA reached -36.74M, while operating income came in at -41.05M.
| Revenue | 8.24M |
| Gross Profit | 3.67M |
| Operating Income | -41.05M |
| Pretax Income | -135.84M |
| Net Income | -135.84M |
| EBITDA | -36.74M |
| EBIT | -41.05M |
| Earnings Per Share (EPS) | -3.90 |
Cash Flow
Aktis Oncology, Inc. produced -38.39M in operating cash flow over the past twelve months. After subtracting -3.99M in capital expenditures, free cash flow totaled -42.38M - equivalent to -1.22 per share.
| Operating Cash Flow | -38.39M |
| Capital Expenditures | -3.99M |
| Free Cash Flow | -42.38M |
| FCF Per Share | -1.22 |
Margins
Aktis Oncology, Inc. operates with a gross margin of -36.19, reflecting its pricing power and cost economics. The operating margin of -498.52 and net profit margin of -1,649.59 provide insight into operational efficiency.
| Gross Margin | -36.19 |
| Operating Margin | -498.52 |
| Pretax Margin | -1,649.58 |
| Profit Margin | -1,649.59 |
| EBITDA Margin | -446.21 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -8,575.97 |
| FCF Yield | -19,733.34 |
Scores
Aktis Oncology, Inc. posts an Altman Z-Score of -16.23, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -16.23 |